The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed advisory board of volunteers who advance the institution’s mission to end cancer, marks the beginning of Fiscal Year 2019 with nine new members, effective Sept. 1:
The University of Texas MD Anderson Cancer Center today was awarded $30 million to support research, core facilities, recruitment and prevention...
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the...
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
The results of the EMBRACA trial were published today in the New England Journal of Medicine...
The University of Texas MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best...
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a...
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children...